【港股通】科伦博泰生物-B逆市升逾4% 抗PD-L1塔戈利单抗获国家药监局批准上市

金吾资讯
02 Jan

金吾财讯 | 科伦博泰生物-B(06990)早盘股价逆市走高,截至发稿,报170港元,涨4.1%,成交额927.09万港元。消息面上,公司发布公告,公司用于治疗既往接受过2线及以上化疗失败的复发或转移性鼻咽癌患者的靶向程序性细胞死亡配体1(PD-L1)的创新人源化单克隆抗体塔戈利单抗(前称KL-A167)(科泰莱)已获中国国家药品监督管理局(NMPA)批准于中国上市。公告提到,本次获批主要基于一项...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10